仁度生物(688193) - 2025 Q4 - 年度业绩预告

Financial Performance Expectations - The company expects a net profit attributable to shareholders of the parent company for 2025 to be between 7.20 million and 10.80 million yuan, an increase of 15.01 million to 18.61 million yuan compared to the previous year, achieving a turnaround from loss to profit [3]. - The net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, is expected to be between -14.50 million and -11.00 million yuan, an increase of 5.06 million to 8.56 million yuan compared to the previous year [3]. - The total profit for 2024 was -15.22 million yuan, with a net profit attributable to shareholders of the parent company at -7.81 million yuan [4]. Cost Management and Efficiency - The company implemented cost reduction and efficiency enhancement measures, leading to a year-on-year decrease in period expenses [5]. - The company strengthened accounts receivable management, recovering some receivables from previous years and reversing some impairment losses [6]. Earnings Forecast Validity - The financial data in the earnings forecast has not yet been audited by a registered accountant [7]. - There are no significant uncertainties affecting the accuracy of the earnings forecast as of the announcement date [7]. - The earnings forecast data is preliminary and subject to change based on the audited annual report to be disclosed later [8].